Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib.
Jingmei YangH Jonathan G LindströmRan FriedmanPublished in: Cancer cell international (2021)
AML patients are not likely to benefit from a quizartinib/pexidartinib rotation protocol. A combination of tyrosine kinase inhibitors (with different molecular targets) might be more useful in the future. Development of specific FLT3 inhibitors that are less sensitive to resistance mutations might also lead to a better outcome.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- liver failure
- prognostic factors
- dendritic cells
- emergency department
- bone marrow
- tyrosine kinase
- aortic dissection
- allogeneic hematopoietic stem cell transplantation
- patient reported outcomes
- hepatitis b virus
- extracorporeal membrane oxygenation
- adverse drug